

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 5/06, A61K 38/08, C07K 14/705, 14/78		A3	(11) International Publication Number: WO 98/45319
			(43) International Publication Date: 15 October 1998 (15.10.98)
(21) International Application Number: PCT/CA98/00322		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 14 April 1998 (14.04.98)			
(30) Priority Data: 60/043,361 10 April 1997 (10.04.97) US			
(71) Applicant (for all designated States except US): MCGILL UNIVERSITY [CA/CA]; 845 Sherbrooke Street West, Montreal, Quebec H3A 1B1 (CA).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): BLASCHUK, Orest, W. [CA/CA]; Suite 1520, 4998 De Maisonneuve West, Westmount, Quebec H3Z 1N2 (CA). GOUR, Barbara, J. [CA/CA]; 5155 Notre Dame de Grace Avenue, Montreal, Quebec H4A 1K6 (CA).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(74) Agents: NASSIF, Omar, A. et al.; Gowling, Strathy & Henderson, Suite 4900, Commerce Court West, Toronto, Ontario M5L 1J3 (CA).		(88) Date of publication of the international search report: 17 December 1998 (17.12.98)	

(54) Title: COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION BETWEEN α -CATENIN and β -CATENIN



(57) Abstract

Modulating agents for inhibiting an interaction between α -catenin and β -catenin are provided. The modulating agents comprise one or more of: (a) a β -catenin HAV motif; (b) a peptide analogue or mimetic of a β -catenin HAV motif; or (c) an antibody or antigen-binding fragment thereof that specifically binds to a β -catenin HAV motif. Methods for using such modulating agents for inhibiting cadherin-mediated cell adhesion in a variety of contexts are also provided.